Background
albuminuria, CKD, chronic kidney disease, diabetes
DISEASE PROGRESSION, CARDIOVASCULAR MORBIDITY, DIABETES
Sodium glucose co-transport 2 inhibitors (SGLT2i) reduce progression
of chronic kidney disease (CKD) and the risk of cardiovascular morbidity and
mortality in a wide range of patients. However, their effects on kidney
disease progression in some patients with CKD are unclear because few
clinical kidney outcomes occurred among such patients in the completed
trials. In particular, some guidelines stratify their level of
recommendation about who should be treated with SGLT2i based on diabetes
status and albuminuria. Our aim was to assess the effects of empagliflozin
on progression of CKD both overall and among specific types of participant
in the EMPA-KIDNEY trial.